The case for & against
Bull & Bear analysis
Bullish
Stevanato Group (NYSE: STVN) is a leading provider of pharmaceutical delivery systems, particularly specializing in integrated solutions for biologics and diagnostics. The company plays a pivotal role in the healthcare sector, capitalizing on the rising demand for drug containment and delivery systems as the prevalence of biologics increases. Stevanato has established itself as a trusted partner for pharmaceutical companies, providing innovative solutions, including its recently authorized Alina® pen injector platform for liraglutide therapies, placing it within the theme of increased reliance on biologics and self-administration devices.
Bull says
- ↑Q2 2026 revenue €302M (+8% YoY); high-value solutions €135.9M (+16% YoY)
- ↑Adjusted EBITDA margin 26% (+280 bps); net profit €23M (+20% YoY)
- ↑Alina® pen injector gains EU approval, driving high-value device adoption
- ↑CapEx €52M focused on Alina and capacity expansion for growth scalability
- ↑Analysts foresee 17.5% upside to $24.74 amid strong quality and profitability factors
Bear says
- ↓Free cash flow -€32M in Q2 due to €52M CapEx, raising liquidity concerns
- ↓Extended sales cycles may lead to erratic revenue recognition and forecasting risk
- ↓Dividend yield only 0.29% offers minimal shareholder returns, dampening sentiment
- ↓Estimated €18M currency headwind on revenue adds volatility amid global operations
- ↓High short interest and low momentum scores reflect market skepticism
- ↓Heavy reliance on GLP-1 therapies faces biosimilar competition threats
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 08-06-2025neutral
Transcript signals
Bull points
- We believe this approach best positions us to be prepared for the recovery, especially considering the time it takes to recruit, hire, and train new staff to achieve full productivity.
- The combination of additional resources, ongoing optimization of our industrial footprint, and streamlining internal processes are helping to improve the overall health of the business.
- We expect that in the long run they will drive operational efficiencies and shorten lead times, which in turn will benefit the segment's margins.
Bear points
- we now anticipate a slow recovery in buyers, particularly easy-fill buyers, which will unfavorably impact our mix of high-value solutions in 2024.
- revenue decreased 1% and 40 basis points on a cost and currency basis to 236 million.
- the lower revenue from easy fill vials was the largest factor in the gross profit margin decrease to 26.4%.
Read full transcript analysis ›